Claire Fuller (UK, chair) emphasised the need for a global
initiative to manage the disease burden of scabies; the principal
challenges include the medical complications of secondary
streptococcal pyoderma, the lack of a diagnostic test and the
need for better understanding of mite immunology, improved
treatment and control. Scabies is estimated to affect around
130 million people, notably in sub-Saharan Africa and tropical
Latin America. Streptococcal pyoderma is an underestimated
complication, with the risk of renal impairment which ranges from
asymptomatic but persistent haematuria to nephrotic syndrome
secondary to acute post streptococcal glomerulonephritis¹.